Citations

Showing 10 of 108094 citations.

Standards of Care for the Health of Transgender and Gender Diverse People, Version 8
Coleman, Eli , Bouman, Walter Pierre , Brown, George R. , Vries, A. de , Deutsch, Madeline B. , Ettner, Randi, Fraser, Lin, Goodman, Michael , Green, J., Hancock, Adrienne B. , Johnson, Thomas W. , Karasic, Dan H., Knudson, Gail, Leibowitz, Scott , Meyer‐Bahlburg, Heino F. L. , Monstrey, S., Motmans, Joz , Nahata, Leena , Reisner, Sari L. , Richards, Christina , Schechter, Loren S. , Tangpricha, Vin , Tishelman, Amy C. , Trotsenburg, M.A.A. van , Winter, Sam , Ducheny, Kelly , Adams, Noah S. , Adrián, T. M., Allen, Luke R. , Azul, David , Bagga, Harjit, Başar, Koray , Bathory, D. S., Belinky, Javier, Berg, Dianne , Berli, Jens U. , Bluebond‐Langner, Rachel , Bouman, Mark‐Bram , Bowers, Marci, Brassard, P., Byrne, Jack, Cargill, C. J., Carswell, Jeremi M. , Chang, Sand C. , Chelvakumar, Gayathri, Corneil, Trevor , Dalke, Katharine B. , Cuypere, Griet De , Vries, Elma De , Devor, Aaron , D’Marco, A., Edmiston, E. Kale , Edwards-Leeper, Laura, Ehrbar, Randall D., Ehrensaft, Diane , Eisfeld, Justus, Elaut, Els , Erickson‐Schroth, Laura, Feldman, Jamie , Garcia, Maurice M. , Gijs, Luk , Green, S. E., Hall, B. P., Hardy, Teresa L. D. , Jacobs, Laura A., Klink, Daniel, Kuper, Laura E. , Kvach, Elizabeth, Malouf, Matthew A., Massey, Ren, Mazur, Tom, McLachlan, Chris tine, Mosser, Scott W., Neira, Paula M. , Nygren, Ulrika , Oates, Jennifer , Pagkalos, Georgios, Patton, J., Rachlin, Katherine, Reed, T., Rider, G. Nic , Ristori, Jiska , Robbins-Cherry, Sally, Roberts, Stephanie , Sabir, K., Seal, Leighton , Sehoole, T. J. , Spencer, K., Amand, Colt St. , Strang, John F. , Taylor, G. B., Vala, L. N., Vencill, Jennifer A. , Wesp, Linda , Rider, G. Nic , Tangpricha, Vin , Roberts, Stephanie A , Radix, Asa E. , Nieder, Timo Ole , Capitán, Luis Pérez , Heijer, Martin den , Dhejne, Cecilia , Fisher, Alessandra D. , Irwig, Michael S. , Jacobs, L. A., Janssen, Aron C. , Johnson, Katherine , Kreukels, Baudewijntje P.C. , McLachlan, Christine , Morrison, Shane D. , Obedin‐Maliver, Juno , Phanuphak, Nittaya , Reed, T., Rodriguez-Wallberg, Kenny A , Rosenthal, Stephen M. , Safer, Joshua D. , Scheim, Ayden I. , Steensma, Thomas D. , Tilleman, Kelly , T’Sjoen, Guy , Mello, Norah M. van , Veale, Jaimie F. , Vincent, Ben , West, Michael A. , Arcelus, Jon

Mayo Clinic

International Journal of Transgender Health | September 6, 2022 | Volume: 23 | Issue: sup1 | Pages: S1-S259

10.1080/26895269.2022.2100644 | PMID 36238954 Get It

Differences of Uric Acid Transporters Carrying Extracellular Vesicles in the Urine from Uric Acid and Calcium Stone Formers and Non-Stone Formers
Lin, Zhijian , Jayachandran, Muthuvel , Haskic, Zejfa , Kumar, Sanjay , Lieske, John C. , Lieske, John C , Kumar, Sanjay

Mayo Clinic

International Journal of Molecular Sciences | September 6, 2022 | Volume: 23 | Issue: 17 | Pages: 10010

10.3390/ijms231710010 | PMID 36077407 Get It

Background: Low urine pH and volume are established risk factors for uric acid (UA) stone disease (UASD). Renal tubular epithelial cells exposed to an acidic pH and/or UA crystals can shed extracellular vesicles (EVs) into the tubular fluid, and these EVs may be a pathogenic biomarker of UASD. Methods: Urinary EVs bearing UA transporters (SLC2A9, SLC17A3, SLC22A12, SLC5A8, ABCG2, and ZNF365) were quantified in urine from UA stone formers (UASFs), calcium stone formers (CSFs), and age-/sex-matched non-stone formers (NSFs) using a standardized and published method of digital flow cytometry. Results: Urinary pH was lower (p < 0.05) and serum and urinary UA were greater (p < 0.05) in UASFs compared with NSFs. Urinary EVs carrying SLC17A3 and SLC5A8 were lower (p < 0.05) in UASFs compared with NSFs. Urinary EVs bearing SLC2A9, SLC22A12, SLC5A8, ABCG2, and ZNF365 were lower (p < 0.05) in CSFs than UASFs, while excretion of SLC17A3-bearing EVs did not differ between groups. Conclusion: EVs bearing specific UA transporters might contribute to the pathogenesis of UASD and represent non-invasive pathogenic biomarkers for calcium and UA stone risk.
Myocarditis Following COVID-19 Vaccine: Incidence, Presentation, Diagnosis, Pathophysiology, Therapy, and Outcomes Put Into Perspective. A Clinical Consensus Document Supported by the Heart Failure Association of the European Society of Cardiology (ESC) an
Heidecker, Bettina , Dagan, Noa , Balicer, Ran D. , Rosano, Giuseppe , Tschöpe, Carsten , Kelle, Sebastian , Poland, Gregory A., Martı́n, Pilar , Hare, Joshua M. , Pantazis, Antonis, Prasad, Sanjay, Lüscher, Thomas F. , Heidecker, Bettina , Tschöpe, Carsten , Eriksson, Urs , Coats, Andrew J.S. , Poland, Gregory A. , Frustaci, Andrea , Klingel, Karin , Cooper, Leslie T. , Imazio, Massimo

Mayo Clinic

European Journal of Heart Failure | September 6, 2022 | Volume: 24 | Issue: 11 | Pages: 2000-2018

10.1002/ejhf.2669 | PMID 36065751 Get It

Abstract Over 10 million doses of COVID-19 vaccines based on RNA technology, viral vectors, recombinant protein, and inactivated virus have been administered worldwide. Although generally very safe, post-vaccine myocarditis can result from adaptive humoral and cellular, cardiac-specific inflammation within days and weeks of vaccination. Rates of vaccine-associated myocarditis vary by age and sex with the highest rates in males between 12 and 39 years. The clinical course is generally mild with rare cases of left ventricular dysfunction, heart failure and arrhythmias. Mild cases are likely underdiagnosed as cardiac magnetic resonance imaging (CMR) is not commonly performed even in suspected cases and not at all in asymptomatic and mildly symptomatic patients. Hospitalization of symptomatic patients with electrocardiographic changes and increased plasma troponin levels is considered necessary in the acute phase to monitor for arrhythmias and potential decline in left ventricular function. In addition to evaluation for symptoms, electrocardiographic changes and elevated troponin levels, CMR is the best non-invasive diagnostic tool with endomyocardial biopsy being restricted to severe cases with heart failure and/or arrhythmias. The management beyond guideline-directed treatment of heart failure and arrhythmias includes non-specific measures to control pain. Anti-inflammatory drugs such as non-steroidal anti-inflammatory drugs, and corticosteroids have been used in more severe cases, with only anecdotal evidence for their effectiveness. In all age groups studied, the overall risks of SARS-CoV-2 infection-related hospitalization and death are hugely greater than the risks from post-vaccine myocarditis. This consensus statement serves as a practical resource for physicians in their clinical practice, to understand, diagnose, and manage affected patients. Furthermore, it is intended to stimulate research in this area.
Awareness, perceptions, and characteristics of internal medicine residents as role models
Toro-Tobón, David , Thornton, Sarah , Toro-Tobon, David

Mayo Clinic

The Clinical Teacher | September 6, 2022 | Volume: 19 | Issue: 6 | Pages: No page available

10.1111/tct.13526 | PMID 36065504 Get It

Abstract Background Role modelling is an essential component of medical education in which trainees incorporate observed characteristics into their personal behaviour and practice style. Data on residents as role models is limited. There are no previous quantitative studies addressing residents as role models from the resident's perspective. Objective This study aimed to dissect the awareness, perception, and positive characteristics of internal medicine (IM) residents as role models. Methods This was a cross sectional study, in which 59 medical students (MS) and 64 IM residents from Medstar Georgetown University Hospital completed a questionnaire on role modelling. Descriptive and comparative analyses between both groups were conducted. Findings Most participants perceived IM residents as role models, but MS were more likely to report that IM residents lack awareness of their role model status. While MS perceived spending more hours with residents, the residents perceived dedicating more of the time spent together to teaching. Most participants denied previous training in role modelling but expressed interest in receiving formal role modelling training. Most participants reported MS behaviours were modified based on their observations of IM residents; however, while most of these behaviours were positive, there were also negative behaviours reported. Conclusion There was a discrepancy between perception and awareness of residents as role models. This characterisation of IM residents as role models sets the ground for the design of interventions to increase awareness and create educational interventions aimed to support residents in their teaching role.
Analysis of College of American Pathologists von Willebrand Factor Proficiency Testing Program
Salazar, Eric , Long, Thomas A., Smock, Kristi J. , Harris, Neil Selwyn, Olson, John D. , Ritter, Jacob, Unold, David, VanSandt, Amanda M., Goodwin, Andrew , Wool, Geoffrey D. , Rollins‐Raval, Marian A. , Chen, Dong , Harris, Neil Selwyn, Chan, Clarence W. , Pham, Huy P.

Mayo Clinic

Seminars in Thrombosis and Hemostasis | September 5, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0042-1757132 Get It

AbstractVon Willebrand factor (VWF) level and/or function is altered in von Willebrand disease (VWD), the most common heritable bleeding disorder worldwide. Laboratory assessment of VWF is continually evolving. Historically, the primary method for the assessment of VWF platelet-binding activity was the ristocetin cofactor assay (VWF:RCo). Contemporary alternative measures of VWF platelet-binding activity include VWF:GPIbR (recombinant; using ristocetin), VWF:GPIbM (recombinant; gain-of-function mutant), and monoclonal antibody. Recently, the American Society of Hematology, International Society on Thrombosis and Haemostasis, National Hemophilia Foundation, and World Federation of Hemophilia collaboration issued guidelines recommending the use of newer assays of VWF platelet-binding activity (VWF: GPIbM, VWF: GPIbR) over VWF:RCo, given known limitations of the VWF:RCo assay. Despite this recommendation, the newer VWF:GPIbM and VWF:GPIbR assays are not United States Food and Drug Administration cleared, limiting their availability in the United States. We sought to assess assay utilization trends, agreement of VWF testing methods, and imprecision of VWF testing (based on assigned sample type) from the College of American Pathologists Proficiency Testing Surveys. The analysis confirms that, while VWF antigen testing has low imprecision, the various VWF activity assays have significant interassay variability, with VWF:RCo showing greater imprecision than the newer GPIb-binding assays. The overall trends in assay utilization reflect the barriers to complete compliance with modern VWD diagnostic guidelines in North America.
Lightning: Another Climate Change Threat
Cunningham, Danielle A. , Cunningham, Danielle A , DeLoughery, Thomas G.

Mayo Clinic

Annals of Internal Medicine | September 5, 2022 | Volume: 175 | Issue: 11 | Pages: 1601-1603

10.7326/m22-1635 | PMID 36063549 Get It

In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia without increasing hypokalemia
Rachmasari, Kharisa, Montori, Víctor M.

Mayo Clinic

Annals of Internal Medicine | September 5, 2022 | Volume: 175 | Issue: 9 | Pages: JC104

10.7326/j22-0063 | PMID 36063558 Get It

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
Menezes, Maria Clara Saad , Raheem, Farah , Mina, Lida A. , Ernst, Brenda , Batalini, Felipe , Mina, Lida, Ernst, Brenda , Batalini, Felipe

Mayo Clinic

Cancers | September 5, 2022 | Volume: 14 | Issue: 17 | Pages: 4332

10.3390/cancers14174332 | PMID 36077867 Get It

Poly-adenosine diphosphate ribose polymerase (PARP) inhibitors (PARPi) are approved for BRCA1/2 carriers with HER2-negative breast cancer in the adjuvant setting with a high risk of recurrence as well as the metastatic setting. However, the indications for PARPi are broader for patients with other cancer types (e.g., prostate and ovarian cancer), involving additional biomarkers (e.g., ATM, PALB2, and CHEK) and genomic instability scores. Herein, we summarize the data on PARPi and breast cancer and discuss their use beyond BRCA carriers.
Real-time prediction of cardiovascular diseases using reservoir-computing and fusion with electronic medical record
Sadasivuni, Sudarsan , Damodaran, Vasundhara , Banerjee, Imon , Sanyal, Arindam , Banerjee, Imon

Mayo Clinic

2022 IEEE 4th International Conference on Artificial Intelligence Circuits and Systems (AICAS) | September 5, 2022 | Volume: No volume available | Issue: No issue available | Pages: 58-61

10.1109/aicas54282.2022.9869980 Get It

Enhanced clinical task-based fMRI metrics through locally low-rank denoising of complex-valued data
Meyer, Nolan , Black, David F. , Welker, Kirk M. , Gray, Erin M. , In, Myung‐Ho , Shu, Yunhong , Trzasko, Joshua D. , Meyer, Nolan K , Huston Iii, John, In, Myung-Ho , Kang, Daehun , Campeau, Norbert G. , Huston, John , Bernstein, Matt A.

Mayo Clinic

The Neuroradiology Journal | September 5, 2022 | Volume: 36 | Issue: 3 | Pages: 273-288

10.1177/19714009221122171 | PMID 36063799 Get It

Objective This study investigates a locally low-rank (LLR) denoising algorithm applied to source images from a clinical task-based functional MRI (fMRI) exam before post-processing for improving statistical confidence of task-based activation maps. Methods Task-based motor and language fMRI was obtained in eleven healthy volunteers under an IRB approved protocol. LLR denoising was then applied to raw complex-valued image data before fMRI processing. Activation maps generated from conventional non-denoised (control) data were compared with maps derived from LLR-denoised image data. Four board-certified neuroradiologists completed consensus assessment of activation maps; region-specific and aggregate motor and language consensus thresholds were then compared with nonparametric statistical tests. Additional evaluation included retrospective truncation of exam data without and with LLR denoising; a ROI-based analysis tracked t-statistics and temporal SNR (tSNR) as scan durations decreased. A test-retest assessment was performed; retest data were matched with initial test data and compared for one subject. Results fMRI activation maps generated from LLR-denoised data predominantly exhibited statistically significant ( p = 4.88×10 –4 to p = 0.042; one p = 0.062) increases in consensus t-statistic thresholds for motor and language activation maps. Following data truncation, LLR data showed task-specific increases in t-statistics and tSNR respectively exceeding 20 and 50% compared to control. LLR denoising enabled truncation of exam durations while preserving cluster volumes at fixed thresholds. Test-retest showed variable activation with LLR data thresholded higher in matching initial test data. Conclusion LLR denoising affords robust increases in t-statistics on fMRI activation maps compared to routine processing, and offers potential for reduced scan duration while preserving map quality.